🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise worldwide, with figures suggesting over 82 million infections each year. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Health officials are increasingly worried about the surge in drug-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a unique collaborative effort for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This approval represents a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Data and Worldwide Availability

As per results published in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which involves an injection and a pill. The trial enrolled nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the rights to register and commercialise the drug in numerous developing nations.

Clinicians directly involved have expressed optimism. The availability of a easy-to-administer therapy of this kind is described as a "revolutionary step" for managing the epidemic. This is viewed as crucial to reduce the burden of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.